Mycoplasma genitalium antimicrobial resistance surveillance (MARS)
Data on the latest findings relating to antimicrobial resistance in Mycoplasma genitalium from specimens collected in sexual health clinics across England.
Applies to England
Documents
Details
Surveillance of antimicrobial resistance in M. genitalium in England is conducted through the M. genitalium Antimicrobial Resistance Surveillance (MARS) Programme. MARS sentinel surveillance data is obtained annually from a network of sexual health services and their associated laboratories. The programme aims to:
- estimate the prevalence of macrolide and fluoroquinolone resistance in M. genitalium infections in individuals attending sentinel sexual health services in England
- determine the demographic, behavioural and clinical factors associated with resistance
- assess treatment outcomes of individuals diagnosed with M. genitalium
Surveillance of antimicrobial resistance is critical in guiding national management guidelines to ensure appropriate treatments. Continued surveillance of antimicrobial resistance in M. genitalium surveillance through MARS will provide a rich resource for informing future updates to management guidelines in the UK.
Pilot collections for this programme were conducted in 2019 and 2020. Previous MARS reports are available from the UK Government Web Archive.
Cases of treatment failure to second-line therapeutics, such as moxifloxacin, should be reported to UK Health security Agency using the HIV and STI Data Exchange
For queries relating to MARS, please contact: [email protected]
Updates to this page
Published 20 November 2020Last updated 13 November 2024 + show all updates
-
Updated with MARS 2023 report and added archive link to previous reports.
-
Added MARS pilot report: data to March 2020.
-
First published.